# Sutent Rechallenge In mRCC Patients

> **NCT01827254** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 61 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **OTHER:** sunitinib: observational study

## Key facts

- **NCT ID:** NCT01827254
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2015-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827254, "Sutent Rechallenge In mRCC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01827254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*